Replimune Group (REPL) Competitors $8.46 -0.73 (-7.94%) Closing price 04:00 PM EasternExtended Trading$8.56 +0.10 (+1.24%) As of 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock REPL vs. AMRX, OGN, MIRM, APLS, DNLI, VCEL, NAMS, AAPG, KYMR, and BHVNShould you be buying Replimune Group stock or one of its competitors? The main competitors of Replimune Group include Amneal Pharmaceuticals (AMRX), Organon & Co. (OGN), Mirum Pharmaceuticals (MIRM), Apellis Pharmaceuticals (APLS), Denali Therapeutics (DNLI), Vericel (VCEL), NewAmsterdam Pharma (NAMS), Ascentage Pharma Group International (AAPG), Kymera Therapeutics (KYMR), and Biohaven (BHVN). These companies are all part of the "pharmaceutical products" industry. Replimune Group vs. Amneal Pharmaceuticals Organon & Co. Mirum Pharmaceuticals Apellis Pharmaceuticals Denali Therapeutics Vericel NewAmsterdam Pharma Ascentage Pharma Group International Kymera Therapeutics Biohaven Amneal Pharmaceuticals (NASDAQ:AMRX) and Replimune Group (NASDAQ:REPL) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, risk, institutional ownership, valuation, earnings, community ranking and analyst recommendations. Which has more risk & volatility, AMRX or REPL? Amneal Pharmaceuticals has a beta of 1.17, suggesting that its stock price is 17% more volatile than the S&P 500. Comparatively, Replimune Group has a beta of 0.68, suggesting that its stock price is 32% less volatile than the S&P 500. Does the MarketBeat Community believe in AMRX or REPL? Replimune Group received 149 more outperform votes than Amneal Pharmaceuticals when rated by MarketBeat users. However, 95.24% of users gave Amneal Pharmaceuticals an outperform vote while only 64.02% of users gave Replimune Group an outperform vote. CompanyUnderperformOutperformAmneal PharmaceuticalsOutperform Votes2095.24% Underperform Votes14.76%Replimune GroupOutperform Votes16964.02% Underperform Votes9535.98% Do analysts recommend AMRX or REPL? Amneal Pharmaceuticals currently has a consensus target price of $11.50, suggesting a potential upside of 56.36%. Replimune Group has a consensus target price of $19.43, suggesting a potential upside of 112.33%. Given Replimune Group's stronger consensus rating and higher probable upside, analysts plainly believe Replimune Group is more favorable than Amneal Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amneal Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Replimune Group 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13 Which has stronger valuation & earnings, AMRX or REPL? Amneal Pharmaceuticals has higher revenue and earnings than Replimune Group. Amneal Pharmaceuticals is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmneal Pharmaceuticals$2.83B0.81-$83.99M-$0.04-183.88Replimune GroupN/AN/A-$215.79M-$3.07-2.98 Is AMRX or REPL more profitable? Replimune Group has a net margin of 0.00% compared to Amneal Pharmaceuticals' net margin of -6.88%. Replimune Group's return on equity of -54.84% beat Amneal Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Amneal Pharmaceuticals-6.88% -346.26% 4.85% Replimune Group N/A -54.84%-42.97% Do insiders and institutionals hold more shares of AMRX or REPL? 31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. Comparatively, 92.5% of Replimune Group shares are owned by institutional investors. 26.6% of Amneal Pharmaceuticals shares are owned by insiders. Comparatively, 8.8% of Replimune Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Does the media favor AMRX or REPL? In the previous week, Amneal Pharmaceuticals and Amneal Pharmaceuticals both had 11 articles in the media. Replimune Group's average media sentiment score of 1.31 beat Amneal Pharmaceuticals' score of 0.97 indicating that Replimune Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amneal Pharmaceuticals 6 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Replimune Group 8 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryReplimune Group beats Amneal Pharmaceuticals on 10 of the 17 factors compared between the two stocks. Get Replimune Group News Delivered to You Automatically Sign up to receive the latest news and ratings for REPL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart REPL vs. The Competition Export to ExcelMetricReplimune GroupBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$703.30M$2.95B$5.41B$8.53BDividend YieldN/A1.72%5.22%4.11%P/E Ratio-2.9731.1426.7719.96Price / SalesN/A411.10395.44121.37Price / CashN/A168.6838.2534.62Price / Book1.463.356.874.60Net Income-$215.79M-$72.17M$3.23B$248.27M7 Day Performance30.53%6.67%5.32%2.28%1 Month Performance4.33%10.13%13.56%16.43%1 Year Performance64.27%-26.77%17.86%8.15% Replimune Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)REPLReplimune Group3.8125 of 5 stars$8.46-7.9%$19.43+129.7%+54.7%$651.55MN/A-2.76210News CoveragePositive NewsUpcoming EarningsHigh Trading VolumeAMRXAmneal Pharmaceuticals3.2515 of 5 stars$7.60+2.6%$11.50+51.3%+10.3%$2.36B$2.83B-11.187,600OGNOrganon & Co.4.7544 of 5 stars$8.69-0.2%$18.00+107.1%-59.8%$2.26B$6.29B2.6110,000High Trading VolumeMIRMMirum Pharmaceuticals4.0809 of 5 stars$45.57+2.9%$59.00+29.5%+79.2%$2.25B$379.25M-22.56140News CoveragePositive NewsEarnings ReportAnalyst ForecastAnalyst RevisionAPLSApellis Pharmaceuticals4.1715 of 5 stars$17.52+1.3%$41.37+136.1%-57.2%$2.20B$781.37M-8.63770Gap UpDNLIDenali Therapeutics4.4205 of 5 stars$14.80+3.0%$33.79+128.3%-29.0%$2.15B$330.53M-5.36430Analyst ForecastVCELVericel2.5508 of 5 stars$42.65+2.2%$60.86+42.7%-14.9%$2.14B$238.54M710.95300Positive NewsNAMSNewAmsterdam Pharma2.5174 of 5 stars$19.22+4.6%$43.00+123.7%-2.5%$2.11B$45.56M-10.224Gap UpAAPGAscentage Pharma Group InternationalN/A$24.20-0.5%N/AN/A$2.11B$980.65M0.00600Positive NewsGap UpKYMRKymera Therapeutics2.7107 of 5 stars$32.17+7.0%$55.53+72.6%-12.7%$2.09B$47.07M-13.75170Analyst ForecastGap DownBHVNBiohaven3.487 of 5 stars$20.47+1.1%$62.54+205.5%-58.7%$2.09BN/A-2.19239Analyst DowngradeGap Down Related Companies and Tools Related Companies Amneal Pharmaceuticals Alternatives Organon & Co. Alternatives Mirum Pharmaceuticals Alternatives Apellis Pharmaceuticals Alternatives Denali Therapeutics Alternatives Vericel Alternatives NewAmsterdam Pharma Alternatives Ascentage Pharma Group International Alternatives Kymera Therapeutics Alternatives Biohaven Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:REPL) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Replimune Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Replimune Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
